Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study
Authors
El Badri, S.Tahir, B.
Balachandran, K.
Bezecny, P.
Britton, Fiona
Davies, M.
Desouza, K.
Dixon, S.
Hills, D.
Moe, M.
Pigott, T.
Proctor, A.
Shah, Y.
Simcock, R.
Stansfeld, A.
Synowiec, A.
Theodoulou, M.
Verrill, M.
Wadhawan, A.
Harper-Wynne, C.
Wilson, C.
Affiliation
Weston Park Hospital, Whitham Rd, Broomhall, Sheffield, S10 2SJ, UK.Issue Date
2021
Metadata
Show full item recordAbstract
Background: Breast cancer incidence increases with age and real-world data is essential to guide prescribing practices in the older population. The aim of this study was to collect large scale real-world data on tolerability and efficacy of palbociclib + AI in the first line treatment of ER+/HER2-advanced breast cancer in those aged ≥75 years. Methods: 14 cancer centres participated in this national UK retrospective study. Patients aged ≥75 years treated with palbociclib + AI in the first line setting were identified. Data included baseline demographics, disease characteristics, toxicities, dose reductions and delays, treatment response and survival data. Multivariable Cox regression was used to assess independent predictors of PFS, OS and toxicities. Results: 276 patients met the eligibility criteria. The incidence of febrile neutropenia was low (2.2%). The clinical benefit rate was 87%. 50.7% of patients had dose reductions and 59.3% had dose delays. The 12- and 24- month PFS rates were 75.9% and 64.9%, respectively. The 12- and 24- month OS rates were 85.1% and 74.0%, respectively. Multivariable analysis identified PS, Age-adjusted Charlson Comorbidity Index (ACCI) and number of metastatic sites to be independent predictors of PFS. Dose reductions and delays were not associated with adverse survival outcomes. Baseline ACCI was an independent predictor of development and severity of neutropenia. Conclusion: Palbociclib is an effective therapy in the real-world older population and is well-tolerated with low levels of clinically significant toxicities. The use of geriatric and frailty assessments can help guide decision making in these patients.Citation
El Badri S, Tahir B, Balachandran K, Bezecny P, Britton F, Davies M, et al. Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study [Internet]. Vol. 60, The Breast. Elsevier BV; 2021. p. 199–205.Journal
BreastDOI
10.1016/j.breast.2021.10.010PubMed ID
34736090Additional Links
https://dx.doi.org/10.1016/j.breast.2021.10.010Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.breast.2021.10.010